–Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composite efficacy sustained at late follow-up visit– SHANGHAI, Feb. 20, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK)’s licensing partner, Venatorx Pharmaceuticals announced that The New…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.